The global amyotrophic lateral sclerosis market is anticipated to touch USD 841.6 million at a healthy 7.89% CAGR during the forecast period (2018-2023). ALS or Amyotrophic Lateral Sclerosis is a neurological ailment which affects the nerve cells in the spinal cord and the brain that controls the voluntary muscles’ activities. Some of the common symptoms of ALS include cramps, muscle weakness, respiratory problems, and fasciculation. This is a progressive neurological disease where gradually patients become dependent on physicians and caregivers increasingly. Often ALS results in respiratory failure as the patient loses the ability of controlling the muscles both in the diaphragm and the chest. Ultimately, it turns fatal.
Get Request Free Sample @ https://www.marketresearchfuture.com/sample_request/5822
There are many factors that are driving the growth of the amyotrophic lateral sclerosis market. Some of these factors as per the Market Research Future (MRFR) report include rising incidences of ALS, increase in awareness among patients, increase in geriatric population, FDA approvals and initiatives taken by the government on R&D activities. On the other hand, factors such as low treatment availability and high treatment cost may hinder the growth of the amyotrophic lateral sclerosis market.
Amyotrophic Lateral Sclerosis Market Segmentation
The amyotrophic lateral sclerosis market has been segmented based on type, treatment, end-user, and regions.
By type, the amyotrophic lateral sclerosis market has been segmented into sporadic ALS and familial ALS. The Sporadic ALS segment is dominating the market. The prevalence of sporadic ALS is relatively high and almost 90% of the cases are sporadic. The cause of sporadic ALS remains unknown and a combination of genetic and environmental risk factors are presumed to be the underlying cause of the diseases. The occurrence of familial ALS is very low and are inherited from genetic mutations.
By treatment, the amyotrophic lateral sclerosis market has been segmented into medication, physical therapy, respiratory therapy, speech therapy, and others. The medication segment is dominating the market as most patients opt for medicines a s a treatment method. Medications are effective and economical.
By end-user, the amyotrophic lateral sclerosis market has been segmented into hospitals, specialty centers, research & academic institutes, and others. The hospitals segment is domineering the markets. Hospitals are generally the first point of treatment and are highly proffered by patients.
Based on region, the amyotrophic lateral sclerosis market covers growth opportunities and latest trends across North America, Europe, Asia Pacific, and the Middle East and Africa. Of these, North America will lead the market during the forecast period owing to support from the government for R&D, rising pool of awareness, the existence of many leading market players, increasing incidence of hypertension, and advanced medical facilities. Canada and the USA are the largest contributors in this region. Europe will have the second largest share in the amyotrophic lateral sclerosis market during the forecast period. The UK, Germany, and France will be the largest contributors in this region. In the APAC region, the amyotrophic lateral sclerosis market is anticipated to grow rapidly owing to the rapidly expanding healthcare infrastructure, increasing the incidence of ALS, the presence of the growing economies mainly India and China, and increasing setups of R&D centers. South Korea, Japan, and Australia are the other vital country-specific markets here. On the other hand, the amyotrophic lateral sclerosis market in the Middle East and Africa will have the smallest share owing to poor countries, inadequate healthcare facilities, lack of education, medical facilities having low standard, lack of awareness and lack of advanced and innovative medical facilities.
Amyotrophic Lateral Sclerosis Market Competitive Landscape
ITF Pharma (USA), Sanofi (France), Mylan N.V. (USA), Mitsubishi Tanabe Pharma America (USA), Ionis Pharmaceutical (USA), Sun Pharmaceutical (India), Ascend Pharmaceuticals LLC (USA), and Apotex Inc. (Canada), Covis Pharma (Switzerland), and Biogen (USA) are the key players in the amyotrophic lateral sclerosis market.
August 2019 – Scientists from the Peking Union Medical College Hospital in China have identified a new type of split-hand index that can assist in distinguishing people with amyotrophic lateral sclerosis at an early stage.
List of Tables
TABLE 1 MARKET SYNOPSIS 15
TABLE 2 LIST OF ASSUMPTIONS 17
TABLE 3 GLOBAL ALS MARKET, BY TYPE, 2020–2027 (USD MILLION) 34
TABLE 4 GLOBAL ALS MARKET FOR SPORADIC ALS, BY REGION, 2020–2027 (USD MILLION) 35
TABLE 5 GLOBAL ALS MARKET FOR FAMILIAL ALS, BY REGION, 2020–2027 (USD MILLION) 35
Browse Complete Report @ https://www.marketresearchfuture.com/reports/amyotrophic-lateral-sclerosis-market-5822
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half- Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312
This post was created with our nice and easy submission form. Create your post!